Autres langues Cybin Inc. OTC Markets

Actions

CLXP.F

CA23256X1006

Cours en clôture OTC Markets Autres places de cotation 00:00:00 01/09/2021			Varia. 5j.	Varia. 1 janv.
2,63 ^CAD	-6,07%		+17,41%	+76,51%

15/03	Mise à jour sectorielle : Les actions du secteur de la santé en baisse vendredi après-midi	MT
15/03	Cybin lance une étude de preuve de concept de phase 2 pour le traitement du trouble anxieux généralisé	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cybin to Participate at the 27th Annual Milken Institute Global Conference	25/04
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18/04
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17/04
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16/04
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16/04
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22/03
Cybin : AGENCY AGREEMENT - Form 6-K	21/03
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19/03
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	18/03
Sector Update: Health Care Stocks Softer Friday Afternoon	15/03
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15/03
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	15/03
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15/03
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	15/03
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3	14/03
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial	14/03
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	14/03
Cybin Inc. - Announces Oversubscribed Private Placement of U.S. $150 Million	14/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cybin Inc. OTC Markets

Actions

CLXP.F

CA23256X1006

Autres langues

Filtres